Prostate Tissue BioBank
Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: Biopsies
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study collects and stores prostate tissue and DNA samples to learn how prostate cancer develops and responds to treatment. It compares people who have inherited gene changes that raise prostate cancer risk with people of similar ages who do not. It is for people having a prostate biopsy or surgery to remove the prostate.
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation. The Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Group 1: You have a confirmed inherited change in a gene linked to prostate cancer risk. The change is known or likely to be harmful.
- Group 1: You are having a prostate biopsy (removal of a small tissue sample) for cancer screening, or a biopsy or prostate removal surgery because you have prostate cancer.
- Group 2 (comparison group): You are having a prostate biopsy for cancer screening, or a biopsy or prostate removal surgery because you have prostate cancer.
Who can't join
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: Carriers (Group 1): 1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene. 2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer Controls (Group 2): 1\. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer Exclusion Criteria: * N/A
Study sites (1)
PA
- University of Pennsylvania · Philadelphia, PA 19104Kara N Maxwell, MD, PhD · Study contact · 215-898-9698Caitlin M Orr, PhD · Study contact · 215-615-3004More trials in Philadelphia